GSK Makes Its Biggest Bet In More Than A Decade, Paying $10.6 Billion For Cancer Drug Developer Nuvalent

GSK agreed to acquire Nuvalent for $10.6 billion in cash, marking its largest acquisition in over a decade. The deal provides GSK with three lung cancer assets including lead drug candidates zidesamtinib and neladalkib for non-small cell lung cancer treatment. The acquisition is expected to contribute to revenue growth and be accretive to sales and core operating profit beginning in 2027.